Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum] by Buhl R, Banerji D

Get full text

Future perspectives of anticholinergics for the treatment of asthma in adults and children by Buhl R, Hamelmann E

Get full text

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD by Buhl R, Banerji D

Get full text

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology by D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR

Get full text

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting by Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R

Get full text

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study by Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T

Get full text

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age by Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R

Get full text

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies by LaForce C, Derom E, Bothner U, Kloer IM, Trampisch M, Buhl R

Get full text

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD by Vogelmeier C, Worth H, Buhl R, Criée C, Lossi NS, Mailänder C, Kardos P

Get full text

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study by Buhl R, Criée C, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H

Get full text

A year in the life of German patients with COPD: the DACCORD observational study by Buhl R, Criée CP, Kardos P, Vogelmeier C, Lossi N, Mailänder C, Worth H

Get full text

Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis by Buhl R, Wilke T, Picker N, Schmidt O, Hechtner M, Kondla A, Maywald U, Vogelmeier CF

Get full text

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol by Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF

Get full text

Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the Uni... by Sethi S, Wright A, Hartgers-Gubbels ES, Hechtner M, Clark B, Wright C, Langham S, Buhl R

Get full text

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. by Pavord, I, Korn, S, Howarth, P, Bleecker, E, Buhl, R, Keene, O, Ortega, H, Chanez, P

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease by Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R

Get full text

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study) by Korn S, Milger K, Skowasch D, Schulz C, Mohrlang C, Wernitz M, Paulsson T, Hennig M, Buhl R

Get full text

Asthma Prevalence and Phenotyping in the General Population: The LEAD (Lung, hEart, sociAl, boDy) Study by Schiffers C, Wouters EF, Breyer-Kohansal R, Buhl R, Pohl W, Irvin CG, Breyer MK, Hartl S

Get full text

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD by Andreas S, McGarvey L, Bothner U, Trampisch M, de la Hoz A, Fležar M, Buhl R, Alter P

Get full text

Severe eosinophilic asthma: a roadmap to consensus. by Buhl, R, Humbert, M, Bjermer, L, Chanez, P, Heaney, L, Pavord, I, Quirce, S, Virchow, J, Holgate, S, Expert Group of the European Consensus Meeting for Severe Eosinophilic Asthma